...
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Evaluation of Clinical Outcomes in Patients Undergoing Dual Vessel Percutaneous Coronary Intervention Using Sirolimus-Eluting Coronary Stent System in India
【24h】

Evaluation of Clinical Outcomes in Patients Undergoing Dual Vessel Percutaneous Coronary Intervention Using Sirolimus-Eluting Coronary Stent System in India

机译:在印度使用西罗莫司洗脱冠状动脉支架系统评估接受双血管经皮冠状动脉介入治疗的患者的临床疗效

获取原文

摘要

Introduction: Coronary artery disease is the most common catastrophic disease in India. The safety and effectiveness of dual vessel sirolimus-eluting stent (SES) implantation (used as an intervention in CAD) is currently unknown in Indian population. The purpose of this study was to investigate one year clinical outcomes of patients with dual vessel coronary artery disease after implantation of the Supralimus-Core SES, in a "real-world" setting.Materials and Methods: We evaluated 60 patients between April-2011 and August-2012, who underwent dual vessel percutaneous coronary intervention (PCI) with the Supralimus- Core SES implantation at the same index procedure. Dual vessels were defined as involvement of two major epicardial vessels (right, left anterior descending, circumflex, or left main coronary arteries) or one major epicardial vessel and a branch ( = 2.5 mm in diameter) originating from another major epicardial vessel. The primary endpoint was target lesion failure (TLF) defined as the composite of cardiac death, myocardial infarction (MI), and clinically-driven target lesion revascularization (TLR) at one year. Secondary endpoint included combined (definite, probable and possible) stent thrombosis (ST).Results: A total of 120 lesions were treated in 60 enrolled patients (mean age 56.0±9.2 y; 80.0% male) with average stent length of 23.1±8.5 mm. Among 60 patients, diabetes, hypertension and hypercholesterolemia were present in 15 (25.0%), 22 (36.7%) and 25 (41.7%) patients respectively. Indications for PCI were unstable angina in 30 (50.0%) patients and stable angina in 11 (18.3%) patients. Overall, 40 (33.3%) lesions were classified as complex (American College of Cardiology/American Heart Association type B2/C). The cumulative TLF rate was 5.0% (n=3) at one year. Cardiac death, MI and clinically-driven TLR occurred in 1 (1.7%), 0 (0%) and 2 (3.3%) patients, respectively at one year follow-up. The Kaplan-Meier curve of the freedom from overall events at one year was 95.0%. According to the Academic Research Consortium definition, there were no events of stent thrombosis during one year.Conclusion: Our study shows that, dual vessel Supralimus- Core SES implantation allows safe and effective treatment with low rates of TLF at one year follow-up in Indian population.
机译:简介:冠状动脉疾病是印度最常见的灾难性疾病。目前在印度人口中尚不知道双血管西罗莫司洗脱支架(SES)植入(用作CAD干预)的安全性和有效性。这项研究的目的是在“真实世界”背景下研究植入Supralimus-Core SES后双血管冠状动脉疾病患者一年的临床结局。材料与方法:我们评估了2011年4月至60日之间的60名患者2012年8月和2012年8月,他们以相同的指标进行了Supralimus-Core SES植入双血管经皮冠状动脉介入治疗(PCI)。双支血管定义为累及两个主要心外膜血管(右,左前降支,回旋支或左主冠状动脉)或一个主要心外膜血管和源自另一个主要心外膜血管的分支(直径= 2.5 mm)。主要终点是目标病变失败(TLF),定义为一年内心脏死亡,心肌梗死(MI)和临床驱动的目标病变血运重建(TLR)的综合。次要终点包括合并的(确定的,可能的和可能的)支架内血栓形成(ST)。结果:60例入组患者(平均年龄56.0±9.2 y;男性80.0%)共治疗了120个病变,平均支架长度为23.1±8.5毫米在60例患者中,糖尿病,高血压和高胆固醇血症分别出现在15例(25.0%),22例(36.7%)和25例(41.7%)中。 PCI的适应症为30例(50.0%)不稳定型心绞痛和11例(18.3%)稳定型心绞痛。总体上,将40个(33.3%)病变分类为复杂病变(美国心脏病学会/美国心脏协会B2 / C型)。一年的累计TLF率为5.0%(n = 3)。在一年的随访中,分别有1例(1.7%),0例(0%)和2例(3.3%)患者发生了心源性死亡,心肌梗死和临床驱动的TLR。一年中不受整体事件影响的Kaplan-Meier曲线为95.0%。根据学术研究联合会的定义,一年内没有发生支架血栓的事件。结论:我们的研究表明,双血管Supralimus-Core SES植入可在一年的随访中以低TLF率进行安全有效的治疗。印度人口。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号